Cargando…
Neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: A SEER based survival analysis
To evaluate the prognostic effect of neoadjuvant chemotherapy (NACT) in advanced epithelial ovarian cancer (EOC) patients with different histological subtype. Stage III/IV EOC patients diagnosed between 2010 and 2018 were identified from the surveillance, epidemiology, and end results database (SEER...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875958/ https://www.ncbi.nlm.nih.gov/pubmed/36705377 http://dx.doi.org/10.1097/MD.0000000000032774 |
_version_ | 1784878061746913280 |
---|---|
author | Liu, Yuexi Ni, Meng Huang, Fanfan Gu, Qiuying Xiao, Yao Du, Xinyue |
author_facet | Liu, Yuexi Ni, Meng Huang, Fanfan Gu, Qiuying Xiao, Yao Du, Xinyue |
author_sort | Liu, Yuexi |
collection | PubMed |
description | To evaluate the prognostic effect of neoadjuvant chemotherapy (NACT) in advanced epithelial ovarian cancer (EOC) patients with different histological subtype. Stage III/IV EOC patients diagnosed between 2010 and 2018 were identified from the surveillance, epidemiology, and end results database (SEER) database and stratified by histological subtype. Kaplan–Meier analysis was used for the assessment of overall survival (OS) cause-specific survival (CSS) before and after matching for baseline characteristics between NACT and primary debulking surgery (PDS) groups. Cox proportional risk model was conducted to identify independent prognostic factors. A total of 13,582 patients were included in the analysis. Of them, 9505 (74.50%) received PDS and 3253 (25.50%) received NACT. Overall, an inferior OS and CSS was observed among patients with high-grade serous carcinoma (HGSC) receiving NACT, while NACT served as a protective factor in clear cell carcinoma and carcinosarcoma in both original cohorts and adjusted cohorts. For other histo-subtypes, PDS showed survival benefit over NACT in certain cohorts of models. Prognostic effect of NACT in advanced EOC differed from pathological subtypes. Although it served as a risk factor for HGSC, patients with less common subtypes may benefit from NACT. |
format | Online Article Text |
id | pubmed-9875958 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-98759582023-01-27 Neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: A SEER based survival analysis Liu, Yuexi Ni, Meng Huang, Fanfan Gu, Qiuying Xiao, Yao Du, Xinyue Medicine (Baltimore) 5600 To evaluate the prognostic effect of neoadjuvant chemotherapy (NACT) in advanced epithelial ovarian cancer (EOC) patients with different histological subtype. Stage III/IV EOC patients diagnosed between 2010 and 2018 were identified from the surveillance, epidemiology, and end results database (SEER) database and stratified by histological subtype. Kaplan–Meier analysis was used for the assessment of overall survival (OS) cause-specific survival (CSS) before and after matching for baseline characteristics between NACT and primary debulking surgery (PDS) groups. Cox proportional risk model was conducted to identify independent prognostic factors. A total of 13,582 patients were included in the analysis. Of them, 9505 (74.50%) received PDS and 3253 (25.50%) received NACT. Overall, an inferior OS and CSS was observed among patients with high-grade serous carcinoma (HGSC) receiving NACT, while NACT served as a protective factor in clear cell carcinoma and carcinosarcoma in both original cohorts and adjusted cohorts. For other histo-subtypes, PDS showed survival benefit over NACT in certain cohorts of models. Prognostic effect of NACT in advanced EOC differed from pathological subtypes. Although it served as a risk factor for HGSC, patients with less common subtypes may benefit from NACT. Lippincott Williams & Wilkins 2023-01-27 /pmc/articles/PMC9875958/ /pubmed/36705377 http://dx.doi.org/10.1097/MD.0000000000032774 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | 5600 Liu, Yuexi Ni, Meng Huang, Fanfan Gu, Qiuying Xiao, Yao Du, Xinyue Neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: A SEER based survival analysis |
title | Neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: A SEER based survival analysis |
title_full | Neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: A SEER based survival analysis |
title_fullStr | Neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: A SEER based survival analysis |
title_full_unstemmed | Neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: A SEER based survival analysis |
title_short | Neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: A SEER based survival analysis |
title_sort | neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: a seer based survival analysis |
topic | 5600 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875958/ https://www.ncbi.nlm.nih.gov/pubmed/36705377 http://dx.doi.org/10.1097/MD.0000000000032774 |
work_keys_str_mv | AT liuyuexi neoadjuvantchemotherapyinadvancedepithelialovariancancerbyhistologyaseerbasedsurvivalanalysis AT nimeng neoadjuvantchemotherapyinadvancedepithelialovariancancerbyhistologyaseerbasedsurvivalanalysis AT huangfanfan neoadjuvantchemotherapyinadvancedepithelialovariancancerbyhistologyaseerbasedsurvivalanalysis AT guqiuying neoadjuvantchemotherapyinadvancedepithelialovariancancerbyhistologyaseerbasedsurvivalanalysis AT xiaoyao neoadjuvantchemotherapyinadvancedepithelialovariancancerbyhistologyaseerbasedsurvivalanalysis AT duxinyue neoadjuvantchemotherapyinadvancedepithelialovariancancerbyhistologyaseerbasedsurvivalanalysis |